Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CollPlant BiotechnologiesFRA:CPT 29 Debt-to-Equity is 0.54 as of Mar. 2026, which is 350% above its 10-year median of 0.12. GuruFocus rates FRA:CPT with a GF Score™ of 29/100 and a GF Value™ of €0.24 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 967 Biotechnology companies, CollPlant Biotechnologies ranks worse than 77.66% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for CollPlant Biotechnologies's Debt-to-Equity or its related term are showing as below:
FRA:CPT'
s Debt-to-Equity Range Over the Past 10 Years
Min: -6.6 Med: 0.12 Max: 1.99
Current: 0.54
During the past 13 years, the highest Debt-to-Equity Ratio of CollPlant Biotechnologies was 1.99. The lowest was -6.60. And the median was 0.12.
FRA:CPT's Debt-to-Equity is ranked worse than 77.66% of 967
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:CPT: 0.54
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
CollPlant Biotechnologies Debt-to-Equity Related Terms
CollPlant Biotechnologies Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CPT vs XBIO, JUNS, ADIL: Debt-to-Equity Comparison
For the Biotechnology subindustry, CollPlant Biotechnologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CollPlant Biotechnologies Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where CollPlant Biotechnologies's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CollPlant Biotechnologies (FRA:CPT) has a Debt-to-Equity of 0.54 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CollPlant Biotechnologies and its competitors. This is 350% above median its historical median of 0.12. According to the industry distribution chart, CollPlant Biotechnologies ranks #751 out of 967 companies in the Biotechnology industry, placing it in the top 77.7%.
Is CollPlant Biotechnologies' Debt-to-Equity too high?
CollPlant Biotechnologies' current Debt-to-Equity of 0.54 is 350% above median its 10-year median of 0.12. The Biotechnology industry median Debt-to-Equity is 0.16. CollPlant Biotechnologies' value of 0.54 is 237.5% above this industry median. Based on the distribution chart, CollPlant Biotechnologies ranks #751 out of 967 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CollPlant Biotechnologies has a GF Score™ of 29/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' Debt-to-Equity compare to XBIO and JUNS?
According to the Biotechnology industry distribution chart, CollPlant Biotechnologies ranks #751 out of 967 companies for Debt-to-Equity. This places CollPlant Biotechnologies in the lower half of its industry. The industry median Debt-to-Equity is 0.16. CollPlant Biotechnologies' value of 0.54 is 237.5% above this benchmark. While the company's 10-year median is 0.12 vs. the industry median of 0.16, CollPlant Biotechnologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CollPlant Biotechnologies's current Debt-to-Equity of 0.54 is 237.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CollPlant Biotechnologies and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CollPlant Biotechnologies's current Debt-to-Equity is 0.54, which is 350% above median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (FRA:CPT) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.24, compared to a current price of €0.27 — trading 10.8% above its estimated fair value. The current Debt-to-Equity is 0.54, which is 350% above median its 10-year median of 0.12 and 237.5% above the Biotechnology industry median of 0.16. CollPlant Biotechnologies' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For CollPlant Biotechnologies (FRA:CPT), the current Debt-to-Equity is 0.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CollPlant Biotechnologies (FRA:CPT) Overvalued in 2026?
Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued.
The current stock price of €0.27 is trading 10.8% above its estimated GF Value™ of €0.24.
GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.
Key valuation signals for FRA:CPT:
Debt-to-Equity: 0.54 (350% above median its 10-year median of 0.12)
GF Value™: €0.24 vs. price of €0.27 (10.8% above fair value)
Industry Position: 237.5% above the Biotechnology median (#751 of 967)
No single metric tells the full story. See the FRA:CPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
29GF Score
Get the complete analysis for FRA:CPT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CPT has been successfully added to your 
